Palonosetron approved by FDA for postoperative nausea and vomiting.
Palonosetron (new indication. The 5-HT3 receptor antagonist can now be used for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. In a Phase III study involving 574 patients undergoing elective gynecologic or abdominal laparoscopic surgery, palonosetron achieved the co-primary endpoint of complete responseno vomiting or use of rescue medication for the first 24 hours after surgery. Palonosetron has been available since 2003 and is also approved for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and severely emetogenic chemotherapy.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.